Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 4.90x is 13% above its 5-year average of 4.33x, around the middle of its 5-year range (3.64x–5.51x).
18.21% above its 12-month average of 4.14x.
Reported annual fiscal-period values; no daily interpolation.
EV/SALES RATIO
4.90x
EV/SALES RATIO AVG TTM
4.14x
EV/SALES RATIO AVG 3Y
3.94x
EV/SALES RATIO AVG 5Y
4.33x
EV/SALES RATIO AVG 10Y
4.30x
EV/SALES RATIO AVG 15Y
4.22x
EV/SALES RATIO AVG 20Y
4.17x
CURRENT VS TTM AVG
+18.21%
CURRENT VS 3Y AVG
+24.21%
CURRENT VS 5Y AVG
+13.03%
CURRENT VS 10Y AVG
+14.00%
CURRENT VS 15Y AVG
+16.01%
CURRENT VS 20Y AVG
+17.51%
SECTOR MEDIAN · HEALTHCARE
4.02x
median of 85 covered companies
CURRENT VS SECTOR MEDIAN
+21.89%
vs the sector median at left
Market Cap
$358.76B
EV/Sales Ratio
0.89x
TTM Avg
0.84x
3Y Avg
1.15x
5Y Avg
1.34x
Market Cap
$234.38B
EV/Sales Ratio
5.88x
TTM Avg
5.28x
3Y Avg
5.36x
5Y Avg
5.59x
Market Cap
$205.42B
EV/Sales Ratio
4.38x
TTM Avg
4.78x
3Y Avg
10.03x
5Y Avg
10.73x
Market Cap
$193.04B
EV/Sales Ratio
4.86x
TTM Avg
4.71x
3Y Avg
4.98x
5Y Avg
4.92x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 4.90x | 4.14x | 3.94x | 4.33x |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 0.89x | 0.84x | 1.15x | 1.34x |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 6.41x | 4.73x | 4.77x | 4.79x |
| AbbVie Inc. (ABBV)vs › | $455.87B | 8.23x | 7.65x | 6.98x | 6.43x |
| AstraZeneca PLC (AZN)vs › | $255.15B | 4.67x | 5.20x | 5.05x | 5.21x |
| Amgen Inc. (AMGN)vs › | $235.85B | 7.42x | 6.34x | 6.58x | 6.39x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 5.88x | 5.28x | 5.36x | 5.59x |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 4.38x | 4.78x | 10.03x | 10.73x |
| Abbott Laboratories (ABT)vs › | $193.04B | 4.86x | 4.71x | 4.98x | 4.92x |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | 6.80x | 6.14x | 5.11x | 4.71x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2025-12-31 | 4.58x |
| 2024-12-31 | 3.71x |
| 2023-12-31 | 3.64x |
| 2022-12-31 | 3.85x |
| 2021-12-31 | 5.51x |
| 2020-12-31 | 4.72x |
| 2019-12-31 | 4.37x |
| 2018-12-31 | 3.71x |
| 2017-12-31 | 4.04x |
| 2016-12-31 | 4.11x |
| 2015-12-31 | 5.04x |
| 2014-12-31 | 5.04x |
| 2013-12-31 | 4.74x |
| 2012-12-31 | 3.73x |
| 2011-12-31 | 3.73x |
| 2010-12-31 | 3.06x |
| 2009-12-31 | 3.87x |
| 2008-12-31 | 3.07x |
| 2007-12-31 | 3.67x |
| 2006-12-31 | 4.53x |
| 2005-12-31 | 4.85x |
| 2004-12-31 | 3.77x |
| 2003-12-31 | 3.68x |
| 2002-12-31 | 2.27x |
| 2001-12-31 | 2.69x |
| 2000-12-31 | 3.51x |
| 1999-12-31 | 3.81x |
| 1998-12-31 | 5.90x |
